French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Wednesday that it has committed an additional USD625m to Sanofi Ventures, its corporate venture capital arm, increasing its total assets under management to over USD1.4bn.
The multi-year investment will focus on early-stage biotech and digital health companies in immunology, rare diseases, neurology, and vaccines.
Since its founding in 2012, Sanofi Ventures has deployed more than USD800m across over 70 companies, participating in private financing rounds, board activities, and IPOs. The fund invests globally across all stages of the private company lifecycle, from seed to crossover, supporting innovation that aligns with Sanofi's long-term strategy.
The additional capital reinforces Sanofi's commitment to fostering pioneering healthcare solutions and advancing technologies that transform patient care.
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
GC Biopharma secures first Latin American approval for BARYCELA Inj.
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil